Jean-Yves Douillard
Institut de Cancérologie de l'Ouest · 110 works · 11,827 citations · h-index 39
Top works
- Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group
- ESMO-Magnitude of Clinical Benefit Scale version 1.1
- Cytokines in Metastatic Renal Cell Carcinoma: Is It Useful to Switch to Interleukin-2 or Interferon After Failure of a First Treatment?
- Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials
- Potential Regional Differences for the Tolerability Profiles of Fluoropyrimidines
- 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up
- 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer
- ERCC1 Isoform Expression and DNA Repair in Non–Small-Cell Lung Cancer
- Subtype Classification of Lung Adenocarcinoma Predicts Benefit From Adjuvant Chemotherapy in Patients Undergoing Complete Resection
- Adjuvant chemotherapy for resected early-stage non-small cell lung cancer
- [13] Enzyme-linked immunosorbent assay for screening monoclonal antibody production using enzyme-labeled second antibody
- Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study
- Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer
- Pooled Analysis of the Prognostic and Predictive Effects of KRAS Mutation Status and KRAS Mutation Subtype in Early-Stage Resected Non–Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy
- Adjuvant Cisplatin and Vinorelbine for Completely Resected Non-small Cell Lung Cancer: Subgroup Analysis of the Lung Adjuvant Cisplatin Evaluation
- Enzyme-linked immunosorbent assay for screening monoclonal antibody production: Use of intact cells as antigen
- Global cancer control: responding to the growing burden, rising costs and inequalities in access
- 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease
- Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers
- Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non–Small-Cell Lung Cancer